Author

R. T. A. Megens

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Hoffmann· 2 shared A. Kapurniotu· 2 shared C. Kontos· 2 shared C. Weber· 2 shared J. Bernhagen· 2 shared L. Maegdefessel· 2 shared M. Brandhofer· 2 shared O. El Bounkari· 2 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Hoffmann

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintDec 28, 2021

MIF-2/D-DT is an atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis

O. El Bounkari, C. Zan, J. Wagner…·J. Bernhagen

This study identifies MIF-2 as an atherogenic chemokine that promotes atherosclerosis and hepatic lipogenesis by acting through CXCR4 and SREBP pathways.

DOI 10.1101/2021.12.28.474328

mouseexperimental assay

𝕏 PostBluesky

ImmunologybioRxivNov 26, 2021

Heterocomplexes between the Atypical Chemokine MIF and the CXC-Motif Chemokine CXCL4L1 Regulate Inflammation and Thrombus Formation

M. Brandhofer, A. Hoffmann, X. Blanchet…·J. Bernhagen

This study identifies a novel interaction between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1, showing that their heterocomplex formation modulates inflammation and thrombus formation.

DOI 10.1007/s00018-022-04539-0

humanproteomics

𝕏 PostBluesky